Breaking News

Tweet TWEET

Illumina Announces New Ruling in its Patent Litigation Against Complete Genomics, Inc.

  Illumina Announces New Ruling in its Patent Litigation Against Complete
  Genomics, Inc.

Business Wire

SAN DIEGO -- November 26, 2012

Illumina, Inc. (NASDAQ:ILMN) announced that Magistrate Judge Elizabeth D.
Laporte of the U.S. District Court for the Northern District of California
granted Illumina’s request to file a motion seeking reconsideration of the
Court’s October 16, 2012 ruling invalidating certain claims of U.S. Patent No.
6,306,597, which is being asserted by Illumina against Complete Genomics, Inc.
Under Judge Laporte’s order, Illumina is permitted to file briefing asking the
Court to reconsider its earlier ruling invalidating claims 14 and 15 of the
‘597 patent. Illumina will seek a January 8, 2013 hearing date on the motion
for reconsideration.

Jay Flatley, Illumina’s President and CEO, stated, “We are very pleased that
the Court has agreed to review its earlier decision invalidating certain
claims of Illumina’s ‘597 patent. We continue to believe that this patent
covers important and novel inventions that Complete Genomics has
misappropriated.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
Investor Relations
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com